333 results about "Acidic amino acids" patented technology

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

A peptide of the following (I) or (II).

• • (I) a peptide represented by the formula B, A-B, B-C or A-B-C in which A, B and C each is represented by the following (1), (2) and (3) and, when it is bonded to other object peptide, it is able to extent the half-life in plasma as compared with the object peptide where the physiological activity of the object peptide is still retained.
  • (II) a peptide comprising a reversed sequence of the peptide of (I); a sequence which is represented by A-B in (I) and A or B is reversed; a sequence which is represented by B-C in (I) and B or C is reversed; or a sequence which is represented by A-B-C in (I) and A, B, C, A and B, B and C or A and C is reserved.
  • (1) A is a peptide comprising 1 to 14 of any amino acid(s)
  • (2) B is a peptide represented by the formula 1:

(Wk-Xl-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s

• • (In the formula 1, W is a basic amino acid; X and Z are any amino acids; Y is an acidic amino acid; k is 1 or 2; l is an integer of 4≧l≧0; m is an integer of 2≧m≧0; 4≧l+m≧0; n is 1 or 2; o is 1 or 2; p is an integer of 4≧p≧0; q is an integer of 2≧q≧0; 4≧p+q≧0; r is 1 or 2; and s is 0 or 1.)
  • (3) C is a peptide comprising 2 to 14 of any amino acids.

A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases.

The invention discloses an enzyme conversion method for preparing gamma-butyric acid. The preparation method comprises employing two mixed acidic amino acids of L-glutamic acid and L-aspartic acid as raw material, mixing the cells of Escherichia.coli AS1.505 with highly active L-glutamic acid decarboxylases and the conversion liquid containing the mixture of L-glutamic acid and L-aspartic acid, implementing enzymatic reaction under the temperature of 28~45íµ, then separating the conversion products by isoelectric point crystallization process or isoelectric point crystallization and ion exchange resin combined method to obtain high purity gamma-butyric acid and L-aspartic acid. The invention solves the problem of the highly effective separation of two acidic mixed amino acids, and obtains gamma-butyric acid with higher additional value, and has advantages of low price, simple operation, short conversion time, and low production cost.

According to the present invention, a process is provided for producing an acyl group-containing composition that includes a step of reacting a long chain N-acyl acidic amino acid anhydride with one or more compounds which have, per molecule, m functional groups of one kind or more selected from the group consisting of hydroxyl, amino and thiol groups in an aqueous solvent and/or a mixed solvent of water and an organic solvent (reaction step). The process makes it possible to produce an acyl group-containing composition that is free from coloration under moderate conditions.

A composition and method is disclosed for inhibiting the corrosion of metals in contact with an aqueous system capable of corroding the metal. The inventive composition contains a substantially water-soluble polymer of an acidic amino acid and at least one water-soluble salt of molybdenum or zinc. The composition is substantially non-toxic and environmentally acceptable and is supplied in a corrosion-inhibition amount to the otherwise metal-corrosive aqueous system.

The invention relates to crystals of an insulin analog in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring neutral or acidic amino acid residue, where phenylalanine (Phe) in position B1 of the B chain can optionally be absent, the crystals being present in the space group R3 (No. 146) with the cell axes A=81.5 ű1 Å and C=33.3 ű1 Å, their preparation and use, and a pharmaceutical composition comprising these crystals.

This invention relates to compositions and methods of delivering therapeutic agents to bone. More specifically, the invention relates to endowing a large molecule vectors i.e., adeno virus, retrovirus, liposomes, micelles, natural and synthetic polymers, or combinations thereof, with the ability to target bone tissue in vivo and with improved stability in the blood, by attaching multiple copies of acid amino acid peptides. One preferred embodiment of the invention relates to endowing an adeno-associated virus (AAV) vector with the ability to target bone-tissue in vivo and improve its stability, by the addition of multiple acidic amino acid peptides attached to the capsid of the viral vector.

A compound represented by the following general formula (I), wherein R¹ and R² represent a hydrocarbon group having 1 to 26 carbon atoms, preferably a linear or branched alkyl group, R³ represents a hydrocarbon group having 7 to 10 carbon atoms, preferably a linear or branched alkyl group, n represents 1 or 2 provided that the acidic amino acid residue in the molecule is L-aspartic acid residue when n is 1 and said acidic amino acid residue is L-glutamic acid residue when n is 2, and a gelling agent for an oil comprising said compound

The invention relates to a method for preparing a novel food additive amino acid chelate, and the method comprises the following steps: acidic amino acid and calcium oxide or calcium hydroxide are chelated in a proper condition to obtain the calcium amino acid chelate; and the calcium amino acid chelate reacts with sulphates of zinc, iron, magnesium, copper, manganese and cobaltic to obtain the corresponding amino acid chelate. The amino acid micro-element chelate produced by the method is characterized in that the products are electric neutrality, do not carry other ions besides amino acid and microelements and have simple process, no environment pollution; the byproduct calcium sulphate is taken as raw auxiliary materials in food and medical fields. Due to the advantages of large dissolubility quality, stable properties, safety and effectiveness and no toxic side effect and the like, the stable amino acid micro-element chelate can bring new commercial opportunities for future healthcare products and medicinal markets.

The invention discloses a method for preparing rare ginsenoside by hydrolyzing ginsenoside with acidic amino acid. Panoxadiol saponins are converted to generate 20R-Rg3, 20S-Rg3, Rg5 and Rk1, and panaxatriol saponins are converted to generate Rg6, F4, Rk3 and Rh4. Compared with an existing preparation process, the hydrolysis capacity of acidic amino acid is more than 10 times of that of neutral amino acid and that of basic amino acid and can better meet requirements of industrial preparation of rare ginsenoside, the defects that the hydrolysis specifity of ginsenoside is poor, the yield is low, the corrosion is high, environment pollution is caused, multiple byproducts are produced and the like due to the fact that a large amount of strong acid and strong base are used are overcome, ginseng resources are fully used, rare ginsenoside is extracted and enriched to the largest extent, the purpose of simple, quick, environment-friendly and low-cost enrichment of rare ginsenoside is achieved, and the method guarantees industrial production and preparation of new medicines.

The invention belongs to the technical field of medicines and discloses cytarabine 5'-O-amino-acid ester, pharmaceutically acceptable salts thereof and a preparation method thereof. The preparation method comprises the following steps of: slowly dropping carbobenzoxy chloride into a solution formed by cytarabine, sodium bicarbonate and N,N-dimethylacetylamide, and obtaining a compound A after reacting at room temperature; using the compound A and N-butyloxy formoxyl-amino acid as raw materials; adding a reagent to the solution to carry out an esterification reaction to obtain the cytarabine 5'-O-amino-acid ester; and then adding acid to obtain a finished product. The pharmaceutically acceptable salts comprise hydrochlorides, sulfates, formates, acetates, mesylates, propionates, butyrates, p-toluene sulphonates, phosphates, bisulfates, maleates, lactates, carbonates, bicarbonates, malonates, and salts formed with acidic amino acids, and the like. The invention can obviously improve the membrane permeability of the cytarabine so as to improve the bioavailability of the cytarabine.

This invention is aimed to provide a stabilized formulation of ramosetron or a pharmaceutically acceptable salt thereof under a temperature/humidity condition, especially at a low content and relates to a stable oral solid drug composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by containing one or two or more members selected from the group consisting of an aliphatic carboxylic acid or an ester thereof, a hydroxycarboxylic acid or an ester thereof, an acidic amino acid, an enolic acid, an aromatic carboxyl compound or an ester thereof, and a carboxyl group-containing high-molecular substance, and to a stabilization method of the same. Also, this invention relates to a therapeutic agent of diarrhea-predominant irritable bowel syndrome containing from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt as an active ingredient.

The invention discloses a soil improvement agent for a saline-alkali land. The soil improvement agent is prepared from the following raw materials in parts by weight: 100-200 parts of humic acid, 50-100 parts of algae mud, 50-100 parts of biochar, 1-5 parts of a biological fungicide, 1-5 parts of a biological enzyme agent, 50-100 parts of pine needle meal, 50-100 parts of brewer's grain, 20-50 parts of sulfur slag, 20-50 parts of bentonite, 100-200 parts of chicken manure, 30-50 parts of straw, 20-30 parts of feather meal and 20-30 parts of earthworm powder. The sulfur ions and sulfuric acid contained in the added sulfur slag are firstly separated out by hot water, are attached to the biological fungicide by virtue of the biological fungicide and then are bound with ions in the saline-alkali land. By further adding an acidic amino acid chelating solution and a bamboo vinegar solution, the pH value of the saline-alkali land is decreased; and by adding the biochar, coconut chaff and rice bran, moisture and water preservation effects are achieved, and soil erosion is prevented.

The invention provides a method for producing composite faintly acid amino acid soap bases. The method for producing the composite faintly acid amino acid soap bases comprises the steps of conducting saponification action with 18%-46% of amino acid surfactant, 10%-31% of water, 12%-29% of triethanolamine, 12%-25% of polyhydric alcohols, 4%-15% of ethyl alcohol and 0.08%-17% of humectant, and obtaining the soap bases. The composite faintly acid amino acid soap bases have the advantages that the PH value of the soap bases is close to that of skin, the PH value is equal to or less than 6.4, and tension or discomfort does not happen to skin after washing. Foam generated through the soap bases is excellent in quality, meanwhile, the appearance of the soap bases is clear and transparent just like crystal, the production process is easy to operate and control comparatively, and the popularization is facilitated. The amino acid surfactant is high in safety to environment and living bodies and has endophilicity to skin and hair.

The invention discloses a preparation method of N-acyl acidic amino acid or a salt thereof. According to the preparation method, fatty acyl chloride and an amino acid are subjected to an amidation reaction under an alkaline condition. The preparation method is characterized in that in the amidation reaction, water is used as a solvent, an acidic amino acid or a salt thereof is used as a main raw material and a small amount of a neutral amino acid or a salt thereof is used as an auxiliary raw material. The preparation method comprises the following steps: under a stirring condition, dropping the fatty acyl chloride into the aqueous solution of the acidic amino acid or the salt thereof; adding an alkali to adjust the pH value of the reaction solution; after a certain amount of fatty acyl chloride is dropped, adding the aqueous solution of the neutral amino acid or the salt thereof, continue to drop the fatty acyl chloride until the dropping is finished and stirring to maintain the reaction. According to the preparation method, the mixed amino acid and the fatty acyl chloride react under a water-phase system, so that the conversion rates of the mixed amino acid and the fatty acyl chloride can be remarkably increased and the amount of residual amino acids is greatly reduced. The product can be directly used as a surfactant after being treated simply, and thus the cost is greatly reduced.

The invention relates to the technical field of biology, and particularly provides a novel coronavirus recombinant antigen coating solution, a pretreatment method, application and a product. The coronavirus recombinant antigen coating solution is composed of a PBS buffer solution, acidic amino acid, BSA, mannitol, trehalose, Proclin300 and water, the stability of the novel coronavirus recombinantantigen in the detection reagent can be effectively improved through mutual coordination and cooperation of all the components, and the sensitivity and specificity of the novel coronavirus antibody detection reagent are effectively improved. Besides, the inventor treats the novel coronavirus recombinant antigen by utilizing DNA hydrolase, randomly decomposes a host DNA fragment in the novel coronavirus recombinant antigen to generate oligonucleotide, eliminates the interference of the DNA fragment on a later antigen detection antibody, and has a remarkable result.